First Oral GLP-1 Agonist Showcased while Approval Pending
ADA 2019 ICYMI: Safety and efficacy of oral semaglutide in patients with T2DM was demonstrated in results of 3 PIONEER program clinical trials. Highlights, here.
Source: ConsultantLive - Category: Internal Medicine Authors: Kenneth J. Bender, PharmD, MA Tags: Diabetes Diabetes Type 2 Source Type: news